Skip to main content
Fig. 1 | Cancer Cell International

Fig. 1

From: Combination of the PI3K inhibitor Idelalisib with the conventional cytostatics cytarabine and dexamethasone leads to changes in pathway activation that induce anti-proliferative effects in B lymphoblastic leukaemia cell lines

Fig. 1

Pro-B ALL cell lines RS4;11 (a–c) and SEM (d–f) exposed with AraC, DEX and IDEL and two drugs combined (AraC+DEX, AraC+IDEL, DEX+IDEL) for 72 h. Influence of mono and combined application on (a, d) proliferation (cell count), (b, e) proliferation and metabolism (WST-1 proliferation assay) and (c, f) apoptosis (Annexin V/PI- staining). A pairwise students t-Test compared to control cells and single compounds reveals significance: *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, [n ≥ 3]. g Plots of apoptotic (Annexin V FITC+ and Propidium iodide-) and necrotic cells (Annexin V FITC + and Propidium iodide +) detected by flow cytometry analysis at 72 h. Data are representative of three independent experiments. Further plots are represented in the Additional file 1: FACS plots

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us